Nuvectis Pharma FY2028 EPS Forecast Lifted by Roth Capital

Key Points

• Roth Capital has raised its FY2028 earnings per share forecast for Nuvectis Pharma to $2.46, up from a previous estimate of $2.43.
• The company reported a quarterly loss of ($0.30) per share, which missed analysts' expectations of ($0.25) per share.
• Insider Marlio Charles Mosseri increased their stake in Nuvectis Pharma by purchasing 5,603 shares at an average price of $7.99 per share.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Roth Capital raised their FY2028 earnings per share (EPS) estimates for Nuvectis Pharma in a research note issued on Tuesday, August 12th. Roth Capital analyst J. Aschoff now expects that the company will earn $2.46 per share for the year, up from their previous estimate of $2.43. The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.01) per share.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.05).

A number of other brokerages have also recently weighed in on NVCT. Wall Street Zen cut Nuvectis Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, June 29th. HC Wainwright lowered their price objective on Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, August 4th.

Nuvectis Pharma Price Performance

Shares of Nuvectis Pharma stock traded up $0.02 during trading on Wednesday, hitting $6.45. The stock had a trading volume of 123,623 shares, compared to its average volume of 145,992. The business has a fifty day moving average of $7.65 and a two-hundred day moving average of $8.27. The firm has a market cap of $164.22 million, a P/E ratio of -5.51 and a beta of -0.26. Nuvectis Pharma has a fifty-two week low of $4.44 and a fifty-two week high of $11.80.

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. increased its holdings in Nuvectis Pharma by 64.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 41,000 shares of the company's stock valued at $401,000 after purchasing an additional 16,000 shares in the last quarter. Northern Trust Corp grew its stake in shares of Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company's stock worth $139,000 after purchasing an additional 10,472 shares during the period. Cubist Systematic Strategies LLC bought a new position in Nuvectis Pharma during the fourth quarter worth about $34,000. Squarepoint Ops LLC bought a new position in Nuvectis Pharma during the fourth quarter worth about $103,000. Finally, Marshall Wace LLP lifted its holdings in Nuvectis Pharma by 191.0% during the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company's stock worth $674,000 after acquiring an additional 81,757 shares in the last quarter. Institutional investors own 96.77% of the company's stock.

Insiders Place Their Bets

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri bought 5,603 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average price of $7.99 per share, for a total transaction of $44,767.97. Following the purchase, the insider directly owned 2,981,806 shares in the company, valued at $23,824,629.94. This trade represents a 0.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders purchased 39,045 shares of company stock worth $314,300. 30.52% of the stock is owned by corporate insiders.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.